(1) See Appendix 1 for a definition of financial indicators
(2) See Appendix 5
(3) U.S. dollar figures obtained by translating euro-denominated figures
at the average exchange rate for the period: 1.374 for Q3 2007 (1.274
for Q3 2006) and 1.344 for 9 months to end September 2007 (1.244 for
9 months to end September 2006)
(4) Excluding net sales of Ambien(R) IR in the United States (from April)
and net sales of Eloxatin(R) in Europe
(5) Comparable net sales
(6) Adjusted EPS excluding selected items for the year ended December 31,
2006 was euro 4.88.
Contacts: Jean-Marc Podvin, firstname.lastname@example.org,
Phone: 33 1 53 77 42 23
This press release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts. These statements
include financial projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future events, operations, products and
services, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expect," "anticipates,"
"believes," "intends," "estimates," "plans" and similar expressions.
Although sanofi-aventis management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of sanofi-aventis, that could cause actual
results and developments to differ materially from those expressed in, or
implied or projected by, the forward- looking information and statements.
These risks and uncertaintie
Copyright©2007 PR Newswire.
All rights reserved